LASOFOXIFENE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C28H31NO2
Molecular Weight	413.5512
Optical Activity	UNSPECIFIED
Defined Stereocenters	2 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OC1=CC=C2[C@H]([C@H](CCC2=C1)C3=CC=CC=C3)C4=CC=C(OCCN5CCCC5)C=C4

InChI

InChIKey=GXESHMAMLJKROZ-IAPPQJPRSA-N

InChI=1S/C28H31NO2/c30-24-11-15-27-23(20-24)10-14-26(21-6-2-1-3-7-21)28(27)22-8-12-25(13-9-22)31-19-18-29-16-4-5-17-29/h1-3,6-9,11-13,15,20,26,28,30H,4-5,10,14,16-19H2/t26-,28+/m1/s1

HIDE SMILES / InChI

Description
Sources: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000977/WC500020092.pdf | https://www.ncbi.nlm.nih.gov/pubmed/16916275 | https://www.ncbi.nlm.nih.gov/pubmed/16368922

Lasofoxifene is an active component of Fablyn. Fablyn is used for the treatment of osteoporosis in postmenopausal women. Lasofoxifene is a nonsteroidal selective estrogen receptor modulator. Lasofoxifene has no effect on CYP2E1- or CYP2D6-mediated drug metabolism and should not affect drugs metabolized by other cytochrome P450 isoenzymes. Common adverse reactions considered to be related to Fablyn therapy were muscle spasms, hot flush and vaginal discharge. Lasofoxifene approved in the EU in 2009 is now withdrawn from use in the European Union.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Estrogen receptor alpha 134 Target ID: CHEMBL206 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16916275 \| http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000977/WC500020092.pdf	Modulator 846		15.0 nM [IC50]
Estrogen receptor beta 113 Target ID: CHEMBL242 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16916275 \| http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000977/WC500020092.pdf	Modulator 846

Conditions

Condition	Modality	Highest Phase	Product
Osteoporosis in postmenopausal women 6 Sources: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000977/WC500020092.pdf	Primary	Withdrawn	Fablyn Approved Use Treatment of osteoporosis in postmenopausal women at increased risk of fracture Launch Date 2009
Advanced breast cancer 6 Sources: http://adisinsight.springer.com/trials/700282284	Primary	Phase III 665	Unknown Approved Use Unknown
Female sexual dysfunction 5 Sources: http://adisinsight.springer.com/drugs/800007522	Primary	Phase II 1147	Unknown Approved Use Unknown

C_max

Value	Dose	Analyte	Population
0.218 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16822276/	0.25 mg single, oral dose: 0.25 mg route of administration: Oral experiment type: SINGLE co-administered:	LASOFOXIFENE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED
0.09 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16397284/	0.01 mg 1 times / day steady-state, oral dose: 0.01 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	LASOFOXIFENE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED
0.25 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16397284/	0.03 mg 1 times / day steady-state, oral dose: 0.03 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	LASOFOXIFENE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED
0.74 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16397284/	0.1 mg 1 times / day steady-state, oral dose: 0.1 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	LASOFOXIFENE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED
2.08 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16397284/	0.3 mg 1 times / day steady-state, oral dose: 0.3 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	LASOFOXIFENE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED
6.43 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16397284/	1 mg 1 times / day steady-state, oral dose: 1 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	LASOFOXIFENE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED
0.169 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16397281/	0.25 mg single, oral dose: 0.25 mg route of administration: Oral experiment type: SINGLE co-administered:	LASOFOXIFENE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
0.173 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16397281/	0.25 mg single, oral dose: 0.25 mg route of administration: Oral experiment type: SINGLE co-administered:	LASOFOXIFENE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
0.214 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16397281/	0.25 mg single, oral dose: 0.25 mg route of administration: Oral experiment type: SINGLE co-administered:	LASOFOXIFENE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: FASTED
0.25 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16707415/	0.25 mg single, oral dose: 0.25 mg route of administration: Oral experiment type: SINGLE co-administered:	LASOFOXIFENE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN
0.5 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16707415/	0.5 mg single, oral dose: 0.5 mg route of administration: Oral experiment type: SINGLE co-administered:	LASOFOXIFENE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN
0.1 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16707415/	0.1 mg single, oral dose: 0.1 mg route of administration: Oral experiment type: SINGLE co-administered:	LASOFOXIFENE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN
0.24 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16707415/	0.25 mg single, oral dose: 0.25 mg route of administration: Oral experiment type: SINGLE co-administered:	LASOFOXIFENE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN
0.44 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16707415/	0.5 mg single, oral dose: 0.5 mg route of administration: Oral experiment type: SINGLE co-administered:	LASOFOXIFENE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN
0.09 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16707415/	0.1 mg single, oral dose: 0.1 mg route of administration: Oral experiment type: SINGLE co-administered:	LASOFOXIFENE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN

AUC

Value	Dose	Analyte	Population
52.7 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16822276/	0.25 mg single, oral dose: 0.25 mg route of administration: Oral experiment type: SINGLE co-administered:	LASOFOXIFENE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED
1.67 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16397284/	0.01 mg 1 times / day steady-state, oral dose: 0.01 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	LASOFOXIFENE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED
5.14 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16397284/	0.03 mg 1 times / day steady-state, oral dose: 0.03 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	LASOFOXIFENE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED
15.7 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16397284/	0.1 mg 1 times / day steady-state, oral dose: 0.1 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	LASOFOXIFENE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED
43.2 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16397284/	0.3 mg 1 times / day steady-state, oral dose: 0.3 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	LASOFOXIFENE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED
137 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16397284/	1 mg 1 times / day steady-state, oral dose: 1 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	LASOFOXIFENE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED
38.1 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16397281/	0.25 mg single, oral dose: 0.25 mg route of administration: Oral experiment type: SINGLE co-administered:	LASOFOXIFENE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
37.1 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16397281/	0.25 mg single, oral dose: 0.25 mg route of administration: Oral experiment type: SINGLE co-administered:	LASOFOXIFENE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
52.6 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16397281/	0.25 mg single, oral dose: 0.25 mg route of administration: Oral experiment type: SINGLE co-administered:	LASOFOXIFENE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: FASTED
45.8 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16707415/	0.25 mg single, oral dose: 0.25 mg route of administration: Oral experiment type: SINGLE co-administered:	LASOFOXIFENE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN
85.5 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16707415/	0.5 mg single, oral dose: 0.5 mg route of administration: Oral experiment type: SINGLE co-administered:	LASOFOXIFENE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN
14.5 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16707415/	0.1 mg single, oral dose: 0.1 mg route of administration: Oral experiment type: SINGLE co-administered:	LASOFOXIFENE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN
45.6 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16707415/	0.25 mg single, oral dose: 0.25 mg route of administration: Oral experiment type: SINGLE co-administered:	LASOFOXIFENE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN
77.5 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16707415/	0.5 mg single, oral dose: 0.5 mg route of administration: Oral experiment type: SINGLE co-administered:	LASOFOXIFENE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN
14.5 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16707415/	0.1 mg single, oral dose: 0.1 mg route of administration: Oral experiment type: SINGLE co-administered:	LASOFOXIFENE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN

T_1/2

Value	Dose	Analyte	Population
196 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16822276/	0.25 mg single, oral dose: 0.25 mg route of administration: Oral experiment type: SINGLE co-administered:	LASOFOXIFENE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED
182 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16397284/	0.03 mg 1 times / day steady-state, oral dose: 0.03 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	LASOFOXIFENE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED
171 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16397284/	0.1 mg 1 times / day steady-state, oral dose: 0.1 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	LASOFOXIFENE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED
147 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16397284/	0.3 mg 1 times / day steady-state, oral dose: 0.3 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	LASOFOXIFENE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED
134 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16397284/	1 mg 1 times / day steady-state, oral dose: 1 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	LASOFOXIFENE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED
193 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16397281/	0.25 mg single, oral dose: 0.25 mg route of administration: Oral experiment type: SINGLE co-administered:	LASOFOXIFENE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
195 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16397281/	0.25 mg single, oral dose: 0.25 mg route of administration: Oral experiment type: SINGLE co-administered:	LASOFOXIFENE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
252 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16397281/	0.25 mg single, oral dose: 0.25 mg route of administration: Oral experiment type: SINGLE co-administered:	LASOFOXIFENE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: FASTED
151.1 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16707415/	0.25 mg single, oral dose: 0.25 mg route of administration: Oral experiment type: SINGLE co-administered:	LASOFOXIFENE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN
134.8 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16707415/	0.5 mg single, oral dose: 0.5 mg route of administration: Oral experiment type: SINGLE co-administered:	LASOFOXIFENE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN
164.3 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16707415/	0.25 mg single, oral dose: 0.25 mg route of administration: Oral experiment type: SINGLE co-administered:	LASOFOXIFENE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN
146.3 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16707415/	0.5 mg single, oral dose: 0.5 mg route of administration: Oral experiment type: SINGLE co-administered:	LASOFOXIFENE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN

F_unbound

Value	Dose	Analyte	Population
0.508% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16397281/	0.25 mg single, oral dose: 0.25 mg route of administration: Oral experiment type: SINGLE co-administered:	LASOFOXIFENE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
0.717% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16397281/	0.25 mg single, oral dose: 0.25 mg route of administration: Oral experiment type: SINGLE co-administered:	LASOFOXIFENE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
0.433% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16397281/	0.25 mg single, oral dose: 0.25 mg route of administration: Oral experiment type: SINGLE co-administered:	LASOFOXIFENE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: FASTED

Doses

Dose	Population	Adverse events
1 mg 1 times / day steady-state, oral Highest studied dose Dose: 1 mg, 1 times / day Route: oral Route: steady-state Dose: 1 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/16735934/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/16735934/	Other AEs: Hot flushes, Leg cramps... Other AEs: Hot flushes (18 patients) Leg cramps (15 patients) Leukorrhea (7 patients) Vaginal bleeding (2 patients) Fractures (5 patients) Leg cramps (7%) Leg cramps (2%) Sources: https://pubmed.ncbi.nlm.nih.gov/16735934/
0.25 mg single, oral Studied dose Dose: 0.25 mg Route: oral Route: single Dose: 0.25 mg Sources: https://pubmed.ncbi.nlm.nih.gov/16397281/	healthy, ADULT Health Status: healthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/16397281/	Other AEs: somnolence, Headache... Other AEs: somnolence (2 patients) Headache (1 pt) nausea (1 pt) Sources: https://pubmed.ncbi.nlm.nih.gov/16397281/
0.25 mg 1 times / day steady-state, oral Studied dose Dose: 0.25 mg, 1 times / day Route: oral Route: steady-state Dose: 0.25 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/16735934/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/16735934/	Other AEs: Breast pain, Hot flushes... Other AEs: Breast pain (4 patients) Hot flushes (24 patients) Leg cramps (20 patients) Leukorrhea (12 patients) Vaginal bleeding (3 patients) Fractures (3 patients) hot flushes (4%) Sources: https://pubmed.ncbi.nlm.nih.gov/16735934/
20 mg single, oral Studied dose Dose: 20 mg Route: oral Route: single Dose: 20 mg Sources: https://pubmed.ncbi.nlm.nih.gov/18372400/	healthy, ADULT Health Status: healthy Age Group: ADULT Sex: M Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/18372400/	Sources: https://pubmed.ncbi.nlm.nih.gov/18372400/

AEs

PubMed

Title	Date	PubMed
Selective estrogen receptor modulator (SERM) lasofoxifene forms reactive quinones similar to estradiol.	2012-07-16	22642258
Lasofoxifene in osteoporosis and its place in therapy.	2010-12	21080249
Third-generation SERMs may face uphill battle.	2010-11-17	21060064
Tipping the balance for the primary prevention of breast cancer.	2010-11-17	21051657
Breast cancer incidence in the randomized PEARL trial of lasofoxifene in postmenopausal osteoporotic women.	2010-11-17	21051656
What is the best balance of benefits and risks among anti-resorptive therapies for postmenopausal osteoporosis?	2010-11	20309524
Lasofoxifene and cardiovascular events in postmenopausal women with osteoporosis: Five-year results from the Postmenopausal Evaluation and Risk Reduction with Lasofoxifene (PEARL) trial.	2010-10-26	20937977
Evidence-based guidelines for the pharmacological treatment of postmenopausal osteoporosis: a consensus document by the Belgian Bone Club.	2010-10	20480148
New selective estrogen receptor modulators (SERMs) in development.	2010-09	20603714
Long-term safety and efficacy of raloxifene in the prevention and treatment of postmenopausal osteoporosis: an update.	2010-08-09	21072271
Therapeutics. Lasofoxifene reduced vertebral fractures in postmenopausal women with osteoporosis.	2010-07-20	20643977
Interest of lasofoxifene in the treatment of osteoporosis. Evaluation of "Lasofoxifene in postmenopausal women with osteoporosis". N Engl J Med 2010;362:686-96.	2010-07	20446861
Safety of bazedoxifene in a randomized, double-blind, placebo- and active-controlled Phase 3 study of postmenopausal women with osteoporosis.	2010-06-22	20569451
Lasofoxifene: Evidence of its therapeutic value in osteoporosis.	2010-06-15	20694069
Lasofoxifene for postmenopausal women with osteoporosis.	2010-06-10	20568310
Lasofoxifene for postmenopausal women with osteoporosis.	2010-06-10	20568309
Lasofoxifene for postmenopausal women with osteoporosis.	2010-06-10	20558377
An innovative method to classify SERMs based on the dynamics of estrogen receptor transcriptional activity in living animals.	2010-04	20197311
SERMs in the prevention and treatment of postmenopausal osteoporosis: an update.	2010-03	20485909
Another selective estrogen-receptor modulator for osteoporosis.	2010-02-25	20181977
Lasofoxifene in postmenopausal women with osteoporosis.	2010-02-25	20181970
Selective estrogen receptor modulator (SERM) for the treatment of osteoporosis in postmenopausal women: focus on lasofoxifene.	2010-02-02	20169039
Endometrial safety: a key hurdle for selective estrogen receptor modulators in development.	2010-01-29	20107426
Gene expression profiling studies of three SERMs and their conjugated estrogen combinations in human breast cancer cells: insights into the unique antagonistic effects of bazedoxifene on conjugated estrogens.	2010-01	19914376
Modulators of androgen and estrogen receptor activity.	2010	21395502
Recent advances in managing osteoporosis.	2009-12-15	20948681
Lasofoxifene: new drug. Osteoporosis: no better than raloxifene.	2009-12	20020572
A randomised, double-blinded, placebo-controlled, trial to determine the individual response in bone turnover markers to lasofoxifene therapy.	2009-12	19665601
Current and emerging pharmacologic therapies for the management of postmenopausal osteoporosis.	2009-10	19857095
Lasofoxifene, a new selective estrogen receptor modulator for the treatment of osteoporosis and vaginal atrophy.	2009-09	19640205
Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009.	2009-08	19535820
New selective estrogen and androgen receptor modulators.	2009-07	19412100
Treatment of osteoporosis with annual iv zoledronic acid: effects on hip fracture.	2009-04	19536314
Effects of various selective estrogen receptor modulators with or without conjugated estrogens on mouse mammary gland.	2009-04	19022889
Designing the ideal selective estrogen receptor modulator--an achievable goal?	2009-02-03	19182697
Lasofoxifene for the prevention and treatment of postmenopausal osteoporosis.	2009	19898646
Progress in osteoporosis and fracture prevention: focus on postmenopausal women.	2009	19849819
Clinical issues regarding cardiovascular disease and selective estrogen receptor modulators in postmenopausal women.	2009	19811253
Docking study of triphenylphosphonium cations as estrogen receptor alpha modulators.	2009	19293997
Bazedoxifene for the prevention of postmenopausal osteoporosis.	2008-12	19337430
Effects of selective oestrogen receptor modulators on proliferation in tissue cultures of pre- and postmenopausal human endometrium.	2008-11	18832036
Metabolism, distribution, and excretion of a next generation selective estrogen receptor modulator, lasofoxifene, in rats and monkeys.	2008-09	18515329
Effects of lasofoxifene on the uterus, vagina, and breast in ovariectomized cynomolgus monkeys (Macaca fascicularis).	2008-08	18501325
Disposition of lasofoxifene, a next-generation selective estrogen receptor modulator, in healthy male subjects.	2008-07	18372400
Hormone-dependent aging problems in women.	2008-06-30	18581581
Activity of three selective estrogen receptor modulators on hormone-dependent responses in the mouse uterus and mammary gland.	2008-06-11	18367319
Selective estrogen receptor modulators: an update on recent clinical findings.	2008-03	18279543
Bazedoxifene: bazedoxifene acetate, TSE 424, TSE-424, WAY 140424.	2008	18457472
[Status of novel bone-targeting SERMs in development].	2007-11-28	18161145
Management of age-related osteoporosis and prevention of associated fractures.	2006-09	18360603

Patents

Sample Use Guides

In Vivo Use Guide

500 ug daily. The tablet may be taken any time of day without regard to food and beverage intake.

Route of Administration: Oral

In Vitro Use Guide

Lasofoxifene was determined to be an extremely potent antagonist to the growth of estrogen-dependent MCF-7 breast cancer cell line (IC50 =0.05 nM).

Name

Type

Language

LASOFOXIFENE

Official Name

English

LASOFOXIFENE [EMA EPAR]

Preferred Name

English

Lasofoxifene [WHO-DD]

Common Name

English

LASOFOXIFENE [MI]

Common Name

English

LASOFOXIFENE [MART.]

Common Name

English

(-)-CIS-5,6,7,8-TETRAHYDRO-6-PHENYL-5-(P-(2-(1-PYRROLIDINYL)ETHOXY)PHENYL)-2-NAPHTHOL

Common Name

English

lasofoxifene [INN]

Common Name

English

Classification Tree Code System Code

WHO-VATC

QG03XC03